The weight loss drug market welcomes a heavyweight player! Several investigational drugs by Roche (RHHBY.US) aiming to break into the top three globally.

Swiss pharmaceutical giant Roche (RHHBY.US) is striving to achieve a double-digit market share in the weight loss drug market and hopes to narrow the gap with its competitor Novo Nordisk A/S Sponsored ADR Class B (NVO.US). The company's CEO, Thomas Schinecker, stated in an interview, "We expect to rank among the top three in the market." Aiming for the global top three Roche is a formidable competitor in the lucrative weight loss drug market, competing fiercely with Eli Lilly (LLY.US) and Novo Nordisk A/S Sponsored ADR Class B. The company's confidence comes from its diverse portfolio of weight loss drugs, including CT-388. After years of preparation, Roche has a rich pipeline in the metabolic field, including the acquisition of Carmot for CT-388 (GLP-1/GIP dual receptor agonist), CT-996 (oral small molecule GLP-1 receptor agonist), and CT-868 (oral GLP-1/GIP dual receptor agonist) obtained through Zealand Pharma, as well as the Petrelintide long-acting insulin analog, the MASH new drug Pegozafermin obtained from 89bio, and the self-developed MSTN monoclonal antibody Emugrobart. In January of this year, Roche announced the promising weight loss effects of CT-388 in a Phase II clinical trial. The trial included 469 obese or overweight patients, testing three subcutaneous injection doses and focusing on changes in weight after 48 weeks of treatment. The results showed that at week 48, patients using the highest dose of 24mg had an average weight loss of 22.5% without reaching a weight loss plateau. In terms of safety, Roche revealed that CT-388 is well-tolerated, with some patients experiencing gastrointestinal reactions similar to other gut-derived pancreatic drugs, but mostly mild to moderate and not significantly affecting treatment. CT-388 has initiated Phase III studies for the treatment of obese or overweight patients with type 2 diabetes in January, and is also conducting Phase II clinical studies for obese or overweight patients with type 2 diabetes (T2D). CT-388 also has the potential for combination therapy with Petrelintide, not only to break through weight loss plateaus but also to delay rebound and improve tolerance, potentially becoming the best treatment in its class. According to Phase 1b clinical data, the fixed-dose combination therapy resulted in an average weight loss of 8.6% after 16 weeks of treatment. Additionally, CT-996 is an orally administered selective GLP-1R agonist currently in Phase II studies for the treatment of obesity and type 2 diabetes. Results from Phase I studies showed an average weight loss of 7.3% in obese patients without type 2 diabetes after 4 weeks of treatment. CT-868 is expected to start Phase III clinical trials for the treatment of type 1 diabetes in 2026. The FGF21 analog Pegozafermin is undergoing Phase III clinical trials for the treatment of metabolic dysfunction-related non-alcoholic steatohepatitis (MASH) in patients with moderate and severe fibrosis (F2 and F3 stages) and cirrhotic patients (F4 stage), and is making significant progress with the potential to be the best in class (BIC) as per Evaluate Pharma data, with peak sales exceeding $5 billion. Emugrobart (GYM329/RG6237) is a monoclonal antibody targeting MSTN that utilizes antibody recycling and scavenging technologies to eliminate latent myostatin from plasma and tissues, potentially addressing the muscle loss issues caused by GLP-1. Roche anticipates that Emugrobart's peak annual sales could reach between $2 billion and $3 billion. Roche's confidence - no patent cliff in sight Thomas Schinecker stated at the 2026 JPM conference, "Our existing product portfolio will drive growth through 2028, and we currently do not see a patent cliff." Against the backdrop of many in the industry facing a patent cliff, the company's oncology business, a key growth engine, provides Roche with the confidence to compete for a spot in the global top three in the weight loss drug market. The oncology business is Roche's largest business segment, encompassing oncology and hematology, including revenues from both blood cancer and non-cancerous blood diseases such as hemophilia. Roche's 2025 financial report showed a 9% year-over-year increase in global pharmaceutical revenue to 47.669 billion Swiss francs, with oncology and hematology business segments contributing a combined revenue of 23.9 billion Swiss francs, nearly half of pharmaceutical revenue. The breast cancer product line is the cornerstone of Roche's oncology business, including trastuzumab (Herceptin), pertuzumab (Perjeta), Phesgo (a fixed-dose combination of pertuzumab and trastuzumab), HER2 ADC ado-trastuzumab emtansine (Kadcyla), PI3Ka inhibitor inavolisib, and PD-L1 inhibitor atezolizumab (Tecentriq). In 2025, Phesgo achieved sales of 2.441 billion Swiss francs, a 48% year-on-year growth and a major driver of growth for Roche's oncology business. Roche's strength in the field of blood cancer is also significant, with medications such as the CD79b ADC drug Polivy (polatuzumab vedotin), the CD20/CD3 bispecific antibody drug Columvi (gentuximab vedotin), and Lunsumio (moxetumomab pasudotox). Polivy achieved a 38% year-on-year revenue growth to 1.47 billion Swiss francs in 2025, mainly benefiting from increased penetration rates in first-line treatment of diffuse large B-cell lymphoma (DLBCL) patients in the United States. Outside of the oncology business, Roche also focuses on neurology, immunology, and ophthalmology treatments, with popular products such as Ocrevus, Evrysdi, Xolair, Gazyva, Actemra, and Vabysmo. To tackle the patent cliff, in addition to its existing products, Roche has adopted an inorganic expansion strategy, with 14 transactions in 2024 and more than 20 transactions since 2025, totaling over $20 billion, covering oncology, immunology, metabolism, and neuroscience. With a rich pipeline ready to succeed its older products, Roche's "no patent cliff" confidence means the company expects to launch as many as 19 new drugs by 2030, with 17 of them potentially surpassing sales of 10 billion Swiss francs and 9 with peak sales potential exceeding 30 billion Swiss francs.